Healthcare / Medical DevicesNasdaqGS
$7.93
-0.58 (-6.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $37.8M · quality 28.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$537M
P/E
19.3x
↓EV/EBITDA
7.8x
↓ROE
12.3%
↑Gross Margin
68.3%
↑Debt/Equity
1.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+8.9%
FCF CAGR
+11.1%
FCF margin
12.7%
FCF / Net income
3.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $568.1M · net income $22.7M · FCF $72.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $568.1M | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M | $321.2M | $340.1M |
| Net Income | $22.7M | $22.7M | $-36.1M | $-156.2M | $-158.7M | $19.4M | $16.4M | $6.9M |
| EBITDA | $99.2M | $99.2M | $36.0M | $-23.1M | $-121.6M | $46.9M | $49.9M | $61.5M |
| EPS | — | — | -0.52 | -2.49 | -2.59 | -0.15 | — | — |
| Gross Margin | 68.3% | 68.3% | 67.7% | 64.1% | 64.6% | 70.3% | 72.7% | 73.3% |
| Operating Margin | 9.9% | 9.9% | 4.0% | 0.4% | -6.8% | 2.8% | 6.6% | 9.2% |
| Net Margin | 4.0% | 4.0% | -6.3% | -30.5% | -31.0% | 4.5% | 5.1% | 2.0% |
| Balance Sheet | ||||||||
| Debt/Equity | 1.60 | 1.60 | 2.27 | 2.27 | 1.29 | 0.74 | — | — |
| Current Ratio | 1.69 | 1.69 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $72.1M | $72.1M | $37.8M | $8.0M | $-15.0M | $9.5M | $55.2M | $38.4M |
| Returns | ||||||||
| ROE | 12.3% | 12.3% | -24.4% | -90.0% | -48.8% | 4.2% | — | — |
| Valuation | ||||||||
| P/E | 19.34 | 19.34 | — | — | — | — | — | — |
| EV/EBITDA | 7.81 | 7.81 | 26.88 | — | — | — | — | — |
| P/B | 2.89 | 2.89 | 4.56 | 1.78 | 0.56 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -0.9% | -0.9% | 11.9% | 0.0% | — | 34.2% | -5.6% | — |
| EPS Growth | — | — | 79.1% | 3.9% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+22.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.52 → n/d
Residual
+22.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.